Prevalence of antiretroviral drug resistance in the HIV-1-infected urban indigent population in San Francisco: A representative study

International Journal of STD and AIDS

Volumn 15, Issue 8, 2004, Pages 543-551

  Holodniy, M ^a,b   Charlebois, E D ^c   Bangsberg, D R ^c   Zolopa, A R ^b   Schulte, M ^a   Moss, A R ^c,d  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

Antiretroviral therapy; HIV; Homeless; Prevalence; Resistance

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENETIC RESISTANCE; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMELESSNESS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; MUTATION RATE; PRIORITY JOURNAL; SOCIOECONOMICS; UNITED STATES; URBAN POPULATION; VIRUS LOAD; VIRUS REPLICATION; VIRUS RESISTANCE;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; COHORT STUDIES; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HOMELESS PERSONS; HUMANS; MALE; MIDDLE AGED; MUTATION; PREVALENCE; SAN FRANCISCO; URBAN HEALTH; VIRAL LOAD;

EID: 4344636326     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/0956462041558212     Document Type: Article

References (61)

1. Adult and adolescent treatment guidelines 3/23/04. Available at: [www.aidsinfo.nih.gov]. Accessed 6/3/04
2. Hirsch MS, Brun-Vezinet F, D'Aquila RT, et al. Antiretroviral drug resistance testing In adult HIV-1 infection: Recommendations of an international AIDS society-USA panel. JAMA 2000;283;2417-26
3. Hecht FM, Grant RM, Petropoulos CJ, et al. Sexual transmission of an HIV-1 variant resistant to multiple reverse transcriptase and protease inhibitors. N Engl J Med 1998;339:307-11
4. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002;347:385-94
5. Balotta C, Berlusconi A, Pan A, et al. Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase protease region: outcome after treatment in recently infected individuals. Antivir Ther 2000;5:7-14
6. Tambussi G, Boeri E, Carrera P, Gianotti N, Lazzarin A. Prevalence of mutation associated to resistance with nucleoside analogues in a cohort of naïve HIV-1 positive subjects during time period 1984-1997. J Biol Regul Homeost Agents 1998;12(1-2 Suppl):32-4
7. Dietrich U, Raudonat I, Wolf E, et al. Indication for increasing prevalence of resistance mutations for protease inhibitors in therapy-naïve HIV-1-positive German patients. AIDS 1999;13:2304-5
8. Perno CF, Cozzi-Lepri A, Balotta C, et al. Low prevalence of primary mutations associated with drug resistance in antiviral-naïve patients at therapy initiation. AIDS 2002;16:619-24
9. Becker-Pergola G, Kataaha P, Johnston-Dow L, Fung S, Jackson JB, Eschleman SH. Analysis of HIV type 1 protease and reverse transcriptase in antiretroviral drug-naïve Ugandan adults. AIDS Res Human Retroviruses 2000;16:807-13
10. Brindeiro RM, Diaz RS, Sabino EC, et al. Brazilian Network for HIV Drug Resistance Surveillance (HIV-BresNet): a survey of chronically infected individuals. AIDS 2003;17:1063-9
11. Sugiura W, Matsuda M, Abumi H, et al. Prevalence of Drug Resistance-Related Mutations among HIV-1 in Japan. Jpn J Infect Dis 1999;52:1-3
12. Gomez-Cano M, Rubio A, Puig T, et al. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naïve and antiretroviral- experienced HIV-infected patients in Spain. AIDS 1998;12:1015-20
13. Simon V, Vanderhoeven J, Hurley A, et al. Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals. AIDS 2002;16:1511-19
14. Grant RM, Hecht FM, Warmerdam M, et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002;288:239-41
15. Brodine SK, Shaffer RA, Starkey MJ, et al. Drug resistance patterns, genetic subtypes, clinical features, and risk factors in military personnel with HIV-1 seroconversion. Ann Intern Med 1999;131:502-6
16. Salomon H, Wainberg MA, Brenner B, et al. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study. AIDS 2000;14:F17-23
17. Balotta C, Berlusconi A, Pan A, et al. Prevalence of HIV-1 resistant strains in recent seroconverters. J Biol Regul Homeost Agents 2000;14:51-7
18. Weinstock H, Respess R, Heneine W, et al. Prevalence of mutations associated with reduced antiretroviral drug susceptibility among human immunodeficiency virus type 1 seroconverters in the United States, 1993-98. J Infect Dis 2000;182:330-3
19. Tamalet C, Pasquier C, Yahi N, et al. Prevalence of drug resistant mutants and virological response in combination therapy in patients with primary HIV-1 infection. J Med Virol 2000;61:181-6
20. Puig T, Perez-Olemeda M, Rubio A, et al. Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in Spain. The ERASE-2 Study Group. AIDS 2000;14:727-32
21. Yahi N, Tamalet C, Tourres C, et al. Mutation patterns of the reverse transcriptase and protease gene human immunodeficiency virus type 1-infected patients undergoing combination therapy: survey 787 sequences. J Clin Microbiol 1999;37:4099-196
22. Schmit JC, Van Laethem K, Ruiz L, et al. Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-strains isolated from patients from different European countries. AIDS 1998;12:2007-15
23. Chantratita W, Jenwitheesuk E, Watitpun C, et al. Prevalence of HIV-1 polymerase gene mutations in pre-treated patients in Thailand. Southeast Asian J Trop Med Public Health 2002;33:80-4
24. Tanuri A, Caridea E, Dantas MC, et al. Prevalence of mutations related to HIV-1 antiretroviral resistance in Brazilian patients failing HAART. J Clin Virol 2002;25:39-46
25. Winters MA, Baxter JD, Mayers DL, et al. Frequency of antiretroviral drug resistance mutations in HIV-1 strains from patients failing triple drug regimens. The Terry Beirn Community Programs for Clinical Research on AIDS. Antivir Ther 2000;5:57-63
26. Pablos-Mendez A, Raviglione MC, Battan R, Ramos-Zuniga R. Drug resistant tuberculosis among the homeless in New York City. N Y State J Med 1990;90:351-5
27. Frieden TR, Fujiwara PI, Wahsko RM, Hamburg MA. Tuberculosis in New York City: turning the tide. N Engl J Med 1995;333:329-33
28. Sontag D, Richardon L. Doctors withhold HIV pill regimen from some. New York Times 1997:A1
29. Roberts KJ, Volberding P. Adherence communication: a qualitative analysis of physician-patient dialogue. AIDS 1999;13:1771-8
30. Gerbert B, Abercombie P, Bronstone A, Clannon K, Bangsberg D. Challenges in adherence: the providers' perspective. AIDS Care 2000;12:409-21
31. Bangsberg D, Tulsky JP, Hecht FM, Moss AR. Protease inhibitors in the homeless. JAMA 1997;278:63-5
32. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-60
33. Celentano DD, Vlahov D, Cohn S, Shadle VM, Obasanjo O, Moore RD. Self-reported antiretroviral therapy in injection drug users. JAMA 1998;280:544-6
34. Strathdee SA, Palepu A, Cornelisse PG, et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA 1998;280:547-9
35. Burham MA, Koegel P. Methodology for obtaining a representative sample of homeless persons : The Los Angeles Skid Row Study. Eval Rev 1988;12:117-52
36. Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 2000;14:357-66
37. Fleiss JL. Statistical methods for rates and proportions, 2nd edn. New York: Wiley, 1981
38. Flynn NM, White C, Nassar N, Cohen SH. Prevalence of RT/PI Mutations in a Large HIV Clinic Population in an Urban Area. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA. September 26-29, 1999 [Abstract 424]
39. McClernon D, Danehower S, Thompson M, et al. Low prevalence of key resistance mutations in underrepresented and incarcerated, antiretroviral therapy naïve, HIV-1 infected adults in North America. International AIDS Society Conference. Buenos Aires. July 2001 [Abstract 586]
40. Hernandez J, Fischl M, Kerkland L, et al. Low phenotypic resistance found in incarcerated, antiretroviral therapy (ART) naïve, HIV-1 infected adults. International AIDS Society Conference. Buenos Aires, July 2001 [Abstract 587]
41. Bangsberg DR, Mundy LM and Tulsky JP. Expanding directly observed therapy: TB to HIV? Am J Med 2000;110:664-7
42. Campo R, Suarez G, Miller N, et al. Efficacy of indinavir (IDV)/ritonavir (RTV)-based regimens (IRBR) among patients with prior protease inhibitor failure. Antiviral Therapy 2000;5(Suppl 2):23 [Abstract 7]
43. Walsh JC, Pozniak AL, Nelson MR, Mandalia S, Gazzard BG. Virologic rebound on HAART in the context of low treatment adherence is associated with a low prevalence of antiretroviral drug resistance. J Acquir Immune Defic Syndr 2002;30:278-87
44. Giordano TP, White AC Jr, Sajja P, et al. Factors associated with the use of highly active antiretroviral therapy in patients newly entering care in an urban clinic. J Acquir Immune Defic Syndr 2003;32:399-405
45. Birk M, Sonnerborg A. Variations in HIV-1 pol gene associated with reduced sensitivity antiretroviral drugs in treatment-naïve patients. AIDS 1998;12:2369-75
46. Kozal MJ, Shah N, Shen N, et al. Extensive polymorphisms observed in HIV-1 clade B protease gene using high density oligonucleotide arrays. Nat Med 1996;2:753-9
47. Mouroux M, Boss P, Yvon-Groussin A, et al. Polymorphism of protease genes in patients infected with HIV and response to therapy including a protease inhibitor. Pathol Biol (Paris) 1999;47:549-52
48. Pellegrin I, Izopet J, Reynes J, et al. Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naïve patients receiving stavudine plus didanosine combination therapy. STADI Group. AIDS 1999;13:1705-9
49. Montes B, Segondy M. Prevalence of the mutational pattern E44D/A and/or V118I in the reverse transcriptase (RT) gene of HIV-1 in relation to treatment with nucleoside analogue RT inhibitors. J Med Virol 2002;66:299-303
50. Hertogs K, Bloor S, De Vroey V, et al. A novel human immunodeficiency virus type-1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V. Antimicrob Agents Chemother 2000;44:568-73
51. Van Vaerenbergh K, Van Laethem K, Albert J, et al. Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues. Antimicrob Agents Chemother 2000;44:2109-17
52. Tamalet C, Yahi N, Tourres C, et al. Multidrug resistance genotypes (insertions in the beta 3-beta 4 finger sub domain and MDR mutations) of HIV-1 reverse transcriptase from extensively treated patients: incidence and association with other resistance mutations. Virology 2000;270:310-16
53. Balotta C, Violin M, Monno L, et al. Prevalence of multiple dideoxynucleoside analogue resistance (MddNR) in a multicenter cohort of HIV-1 infected Italian patients with virologic failure. J Acquir Immune Defic Syndr 2000;24:232-40
54. Cabana M, Clotet B, Martinez MA. Emergence and genetic evolution of HIV-1 variants with mutations conferring resistance to multiple reverse transcriptase and protease inhibitors. J Med Virol 1999;59:480-90
55. Quiros-Roldan E, Moretti F, Airoldi M, et al. Long-term benefit of genotypic-guided therapy and prevalence of multinucleoside resistance in an Italian group of antiretroviral multiexperienced patients. J Clin Lab Anal 2001;15:127-30
56. Maquelier B, Race E, Tamalet C, et al. Genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 variants with insertions or deletions in the reverse transcriptase (RT): multi-center study of patients treated with RT inhibitors. Antimicrob Agents Chemother 2001;45:1836-42
57. Clevenbergh P, Cua E, Dam E, et al. Prevalence of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance-associated mutations and polymorphisms in NNRTI-naive HIV-infected patients. HIV Clin Trials 2002;3:36-44
58. Izopet J, Massip P, Souyris C, et al. Shift in HIV resistance genotype after treatment interruption and short-term antiviral effect following a new salvage regimen. AIDS 2000;14:2247-55
59. Van Laethem K, Van Vaerenbergh K, Schmit JC, et al. Phenotypic assays and sequencing are less sensitive than point mutation assays for detection of resistance in mixed HIV-1 genotypic populations. J Acquir Immune Defic Syndr 1999;22:107-18
60. Trabaud MA, Leriche-Geurin K, Regis C, et al. Prevalence of primary resistance to zidovudine and lamivudine in drug-naïve human immunodeficiency virus type-1 infected patients: high proportion of reverse transcriptase codon 215 mutant in circulating lymphocytes and free virus. J Med Virol 2000;61:352-9
61. Richman D, Bozzette S, Morton S, et al. The prevalence of antiretroviral drug resistance in the US. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, December 15-18, 2001 [Abstract LB-17]